Sign inJoin waitlistJoin the waitlist

Ola Landgren

Translational Science Lead · University of Miami/Jackson Health System

Credentials: · · · · ·

History

Tumor Biology Program · University of Miami/Jackson Health System
Present
Translational and Clinical Oncology Program Research Program · University of Miami/Jackson Health System
Present
Sylvester Comprehensive Cancer Center Division · University of Miami/Jackson Health System
Present

Karolinska Institutet
1999–2002
Nykoping Hospital
1996–1999
Karolinska Hospital
1995–1996
Karolinska Institutet
1991–1995

Research

International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma
Review · The Lancet Oncology · 2014 · 3,783 citations
International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma
Review · The Lancet Oncology · 2016 · 2,602 citations
Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study
Blood · 2009 · First of 12 authors · Corresponding · 860 citations

NK
Neha Korde
95 papers · 9 as a fellow
SM
Sham Mailankody
78 papers · 35 as a resident
MH
Malin Hultcrantz
77 papers · 4 as a fellow
FM
Francesco Maura
73 papers
Benjamin Diamond
57 papers
AL
Alexander Lesokhin
55 papers
Dickran Kazandjian
52 papers · 5 as a fellow
Saad Usmani
44 papers
HH
Hani Hassoun
43 papers
KM
Kylee Maclachlan
41 papers · 35 as a fellow
Gareth Morgan
39 papers
SG
Sergio Giralt
37 papers

Grants

The Sylvester Cancer Center Support Grant
National Cancer Institute · P30
Project lead · $96.4K · University of Miami School of Medicine
2019–2029
cd38-Targeted Immunopet of Myeloma: Phase 2 Trial of Clinical Applications
National Cancer Institute · R01
PI · $2M · Hoag Memorial Hospital Presbyterian
2020–2026
Myeloma Precursor Disease Among WTC Responders
NIOSH · U01
PI · $492.6K · Albert Einstein College of Medicine
2020–2023
Early Detection of Hematologic Malignancies in New York City Firefighters Exposed To World Trade Center Dust After The 9/11 Attacks
NIOSH · U01
PI · $999.7K · Albert Einstein College of Medicine, Inc
2017–2020

Clinical trials

FAST-M: Prolonged Overnight Fasting and Mediterranean Dietary Intervention for Patients With Multiple Myeloma or Its Precursor Disease
Principal investigator · Recruiting
University of Miami
2026–2029
ERd Combination Treatment in Newly Diagnosed Multiple Myeloma (ADVANCE 2.0)
Principal investigator · Recruiting · Phase 2
University of Miami
2025–2030
Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients With Relapsed/Refractory Multiple Myeloma
Principal investigator · Recruiting · Phase 2
Benjamin T Diamond, MD
2024–2031
Teclistamab in Combination With Daratumumab for High-Risk Smoldering Myeloma: A Clinical and Correlative Phase 2 Immuno-Oncology Study (the REVIVE Study)
Principal investigator · Recruiting · Phase 2
Carl Ola Landgren, MD, PhD
2023–2029